BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9454971)

  • 1. Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.
    Busca A; Miniero R; Besenzon L; Cordero di Montezemolo L; Cenni M; Fagioli F; Sandri A; Vassallo E; Ricardi U; Madon E
    Childs Nerv Syst; 1997; 13(11-12):572-7. PubMed ID: 9454971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
    Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
    Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
    Guruangan S; Dunkel IJ; Goldman S; Garvin JH; Rosenblum M; Boyett JM; Gardner S; Merchant TE; Gollamudi S; Finlay JL
    J Clin Oncol; 1998 Jul; 16(7):2486-93. PubMed ID: 9667268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
    Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
    Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
    Finlay JL; Goldman S; Wong MC; Cairo M; Garvin J; August C; Cohen BH; Stanley P; Zimmerman RA; Bostrom B; Geyer JR; Harris RE; Sanders J; Yates AJ; Boyett JM; Packer RJ
    J Clin Oncol; 1996 Sep; 14(9):2495-503. PubMed ID: 8823328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
    Finlay JL; Dhall G; Boyett JM; Dunkel IJ; Gardner SL; Goldman S; Yates AJ; Rosenblum MK; Stanley P; Zimmerman RA; Wallace D; Pollack IF; Packer RJ;
    Pediatr Blood Cancer; 2008 Dec; 51(6):806-11. PubMed ID: 18802947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
    Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
    Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
    Papadopoulos KP; Balmaceda C; Fetell M; Kaufman E; Vahdat LT; Bruce J; Sisti M; Isaacson S; De LaPaz R; Savage DG; Troxel A; Antman KH; Hesdorffer CS
    J Neurooncol; 1999 Sep; 44(2):155-62. PubMed ID: 10619499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
    Graham ML; Herndon JE; Casey JR; Chaffee S; Ciocci GH; Krischer JP; Kurtzberg J; Laughlin MJ; Longee DC; Olson JF; Paleologus N; Pennington CN; Friedman HS
    J Clin Oncol; 1997 May; 15(5):1814-23. PubMed ID: 9164190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High-dose chemotherapy in relapse of medulloblastoma in young children].
    Dupuis-Girod S; Hartmann O; Benhamou E; Doz F; Mechinaud F; Bouffet E; Coze C; Kalifa C
    Bull Cancer; 1997 Mar; 84(3):264-72. PubMed ID: 9207872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
    Kalifa C; Hartmann O; Demeocq F; Vassal G; Couanet D; Terrier-Lacombe MJ; Valteau D; Brugieres L; Lemerle J
    Bone Marrow Transplant; 1992 Apr; 9(4):227-33. PubMed ID: 1534708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.
    Mason WP; Grovas A; Halpern S; Dunkel IJ; Garvin J; Heller G; Rosenblum M; Gardner S; Lyden D; Sands S; Puccetti D; Lindsley K; Merchant TE; O'Malley B; Bayer L; Petriccione MM; Allen J; Finlay JL
    J Clin Oncol; 1998 Jan; 16(1):210-21. PubMed ID: 9440745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
    Finlay JL; August C; Packer R; Zimmerman R; Sutton L; Freid A; Rorke L; Bayever E; Kamani N; Kramer E
    J Neurooncol; 1990 Dec; 9(3):239-48. PubMed ID: 1964962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
    Grovas AC; Boyett JM; Lindsley K; Rosenblum M; Yates AJ; Finlay JL
    Med Pediatr Oncol; 1999 Aug; 33(2):83-7. PubMed ID: 10398181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.